This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Brierly DJ, Gospodarowicz MK, Witekind C, editors. TNM classification of malignant tumours. 8th edition. Oxford: Wiley-Blackwell; 2017. p. 114-20.BrierlyDJGospodarowiczMKWitekindCTNM classification of malignant tumours8th editionOxfordWiley-Blackwell201711420Search in Google Scholar
Sobin LH, Gospodarowicz MK, Witekind C, editors. TNM classification of malignant tumours. 7th edition. Oxford: Wiley-Blackwell; 2009. p. 138-46.SobinLHGospodarowiczMKWitekindCTNM classification of malignant tumours7th editionOxfordWiley-Blackwell200913846Search in Google Scholar
Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-14. doi: 10.1097/JTO.0b013e31812f3c1aGoldstrawPCrowleyJChanskyKGirouxDJGroomePARami-PortaRet alThe IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumoursJ Thorac Oncol200727061410.1097/JTO.0b013e31812f3c1aOpen DOISearch in Google Scholar
Kligerman S, Digumarthy S. Staging of non small cell lung cancer using integrated PET/CT. AJR Am J Roentgenol 2009; 193:1203-11. doi: 10.2214/ AJR.09.3193KligermanSDigumarthySStaging of non small cell lung cancer using integrated PET/CTAJR Am J Roentgenol200919312031110.2214/AJR.09.3193Open DOISearch in Google Scholar
Kim SY, Kim JS, Park HS, Cho MJ, Kim JO, Kim JW, et al. Screening of brain metastasis with limited magnetic resonance imaging (MRI): clinical implications of using limited brain MRI during initial staging for non-small cell lung cancer patients. J Korean Med Sci 2005; 20: 121-6. doi: 10.3346/ jkms.2005.20.1.121KimSYKimJSParkHSChoMJKimJOKimJWet alScreening of brain metastasis with limited magnetic resonance imaging (MRI): clinical implications of using limited brain MRI during initial staging for non-small cell lung cancer patientsJ Korean Med Sci200520121610.3346/jkms.2005.20.1.121Open DOISearch in Google Scholar
Rami-Porta R, Asamura H, Goldstraw P. Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities. Transl Lung Cancer Res 2015; 4: 415-23. doi: 10.3978/j.issn.2218-6751.2015.07.11Rami-PortaRAsamuraHGoldstrawPPredicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunitiesTransl Lung Cancer Res201544152310.3978/j.issn.2218-6751.2015.07.11Open DOISearch in Google Scholar
Huang A, Li R, Zhao J, Wang X, Jin B, Niu Y, et al. Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation. Thorac Cancer 2016; 7: 614-8. doi: 10.1111/1759-7714.12364HuangALiRZhaoJWangXJinBNiuYet alEpidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutationThorac Cancer20167614810.1111/1759-7714.12364Open DOISearch in Google Scholar
Park HJ, Oh HJ, Kim KH, Kim TO, Park CK, Shin HJ, et al. Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR-tyrosine kinase inhibitor treatment response. Thorac Cancer 2016; 7: 639-47. doi: 10.1111/1759-7714.12378ParkHJOhHJKimKHKimTOParkCKShinHJet alQuantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR-tyrosine kinase inhibitor treatment responseThorac Cancer201676394710.1111/1759-7714.12378Open DOISearch in Google Scholar
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016; 375: 1823-33. doi: 10.1056/NEJMoa1606774ReckMRodríguez-AbreuDRobinsonAGHuiRCsősziTFülöpAet alPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med201637518233310.1056/NEJMoa1606774Open DOISearch in Google Scholar
Eberhardt WEE, Mitchell A, Crowley J, Kondo H, Kim YT, Turrisi A 3rd, et al. The IASLC Lung Cancer Staging Project Proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. Thorac Oncol 2015; 10: 1515-22. doi: 10.1097/ JTO.0000000000000673EberhardtWEEMitchellACrowleyJKondoHKimYTTurrisiAet alThe IASLC Lung Cancer Staging Project Proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancerThorac Oncol20151015152210.1097/JTO.0000000000000673Open DOISearch in Google Scholar
Stanic K, Zwitter M, Hitij NT, Kern I, Sadikov A, Cufer T. Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol 2014; 48: 173-83. doi: 10.2478/raon-2014-0016StanicKZwitterMHitijNTKernISadikovACuferTBrain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survivalRadiol Oncol2014481738310.2478/raon-2014-0016Open DOISearch in Google Scholar
Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 2017; 389: 917-29. doi: 10.1016/S0140-6736(17)30123-XSoriaJCTanDSWChiariRWuYLPaz-AresLWolfJet alFirst-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 studyLancet20173899172910.1016/S0140-6736(17)30123-XOpen DOISearch in Google Scholar
Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget 2017; 8: 21903-17. doi: 10.18632/oncotarget.15746DuruisseauxMBesseBCadranelJPérolMMennecierBBigay-GameLet alOverall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective studyOncotarget20178219031710.18632/oncotarget.15746540063328423535Open DOISearch in Google Scholar
Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378: 113-25. doi: 10.1056/NEJMoa1713137SoriaJCOheYVansteenkisteJReungwetwattanaTChewaskulyongBLeeKHet alOsimertinib in untreated EGFR-mutated advanced non-small-cell lung cancerN Engl J Med20183781132510.1056/NEJMoa171313729151359Open DOISearch in Google Scholar
Lee CK, Man J, Lord S, Cooper W4, Links M, Gebski V, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis. JAMA Oncol 2018; 4: 210-16. doi: 10.1001/jamaoncol.2017.4427LeeCKManJLordSCooperW4LinksMGebskiVet alClinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysisJAMA Oncol201842101610.1001/jamaoncol.2017.4427583859829270615Open DOISearch in Google Scholar
Kaderbhaï C, Tharin Z, Ghiringhelli F. The role of molecular profiling to predict the response to immune checkpoint inhibitors in lung cancer. Cancers (Basel) 2019; 11: E201. doi: 10.3390/cancers11020201KaderbhaïCTharinZGhiringhelliFThe role of molecular profiling to predict the response to immune checkpoint inhibitors in lung cancerCancers (Basel)201911E20110.3390/cancers11020201640695730744168Open DOISearch in Google Scholar
Kaplan EL, Paul Meier. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53: 457-81.KaplanELPaulMeierNonparametric estimation from incomplete observationsJournal of the American Statistical Association1958534578110.1007/978-1-4612-4380-9_25Search in Google Scholar
Rami-Porta R, Goldstraw P. Strength and weakness of the new TNM classification for lung cancer. Eur Respir J 2010; 36: 237-9. doi: 10.1183/09031936.00016210Rami-PortaRGoldstrawPStrength and weakness of the new TNM classification for lung cancerEur Respir J201036237910.1183/09031936.0001621020675779Open DOISearch in Google Scholar
Doroshow DB, Herbst RS. Treatment of advanced non-small cell lung cancer in 2018. JAMA Oncol 2018; 4: 569-70. doi: 10.1001/jamaoncol.2017.5190DoroshowDBHerbstRSTreatment of advanced non-small cell lung cancer in 2018JAMA Oncol201845697010.1001/jamaoncol.2017.519029494728Open DOISearch in Google Scholar
Hendriks LE, Derks JL, Postmus PE, Damhuis RA, Houben RM, Troost EG, et al. Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: results from a population-based study. Eur J Cancer 2015; 51: 2534-44. doi: 10.1016/j. ejca.2015.08.008HendriksLEDerksJLPostmusPEDamhuisRAHoubenRMTroostEGet alSingle organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: results from a population-based studyEur J Cancer20155125344410.1016/j.ejca.2015.08.00826323530Open DOISearch in Google Scholar
National Comprehensive CancerNetwork. Non-small cell lung cancer. National Comprehensive Cancer Network Guidelinese. v.5. 2018. [cited 2018 Jul 25]. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfNational Comprehensive CancerNetwork. Non-small cell lung cancer. National Comprehensive Cancer Network Guidelinese. v.52018[cited 2018 Jul 25]. Available athttp://www.nccn.org/professionals/physician_gls/pdf/nscl.pdfSearch in Google Scholar
Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Levra MG, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27(Suppl 5): v1-27, 2016. doi: 10.1093/annonc/mdw326NovelloSBarlesiFCalifanoRCuferTEkmanSLevraMGet alMetastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201627Suppl 5v12710.1093/annonc/mdw32627664245Open DOISearch in Google Scholar
Folkert MR, Timmerman R. Review of treatment options for oligometastatic non-small cell lung cancer. Clin Adv Hematol Oncol 2015; 13:186-93. PMID: 26352427FolkertMRTimmermanRReview of treatment options for oligometastatic non-small cell lung cancerClin Adv Hematol Oncol20151318693PMID: 26352427Search in Google Scholar
Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol 2017; 3: 827-31. doi: 10.1001/ jamaoncol.2016.3834SperdutoPWYangTJBealKPanHBrownPDBangdiwalaAet alEstimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA)JAMA Oncol201738273110.1001/jamaoncol.2016.3834582432327892978Open DOISearch in Google Scholar
Miyaji N, Miki T, Itoh Y, Shimada J, Takeshita T, Churei H, et al. Radiotherapy for adrenal gland metastasis from lung cancer: report of three cases. Radiat Med 1999; 17: 71-5. PMID: 10378656MiyajiNMikiTItohYShimadaJTakeshitaTChureiHet alRadiotherapy for adrenal gland metastasis from lung cancer: report of three casesRadiat Med199917715PMID: 10378656Search in Google Scholar
Pardo Aranda F, Larrañaga Blanc I, Rivero Déniz JR, Trujillo JC, Rada Palomino A, García-Olivares E, et al. Surgical treatment of lung cancer with synchronous adrenal metastases: adrenalectomy first. Cir Esp 2017; 95: 97101. doi: 10.1016/j.ciresp.2017.01.003PardoAranda FLarrañagaBlanc IRiveroDéniz JRTrujilloJCRadaPalomino AGarcía-OlivaresEet alSurgical treatment of lung cancer with synchronous adrenal metastases: adrenalectomy firstCir Esp2017959710110.1016/j.ciresp.2017.01.00328223072Open DOISearch in Google Scholar
Kratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, Woodard GA, et al. Incorporation of a molecular prognostic classifier improves conventional non-small cell lung cancer staging. J Thorac Oncol 2019; 14: 1223-32. doi: 10.1016/j.jtho.2019.03.015KratzJRHaroGJCookNRHeJVanDen Eeden SKWoodardGAet alIncorporation of a molecular prognostic classifier improves conventional non-small cell lung cancer stagingJ Thorac Oncol20191412233210.1016/j.jtho.2019.03.01530959120Open DOISearch in Google Scholar
